Beverly Everitt
Nurse Practitioner · Omaha, NENPI 1023124492
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), speaking fees and gifts — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Mannkind Corporation at 42.2% of the total. Reporting peaked in 2023 at $6,544 and has fallen 99.8% since, to $13 in 2024. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $34.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$5K
- Lilly USA, LLC$1K
- Zealand Pharma US, Inc.$843
- Novo Nordisk$590
- Insulet Corporation$517
- Medtronic$512
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$5,35044%
- Travel & lodging$590%
- Food & beverage$6,72355%
- Education$120%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 16 | $5,152 |
| Lilly USA, LLC | 74 | $1,366 |
| Zealand Pharma US, Inc. | 7 | $843 |
| Novo Nordisk | 36 | $590 |
| Insulet Corporation | 26 | $517 |
| Medtronic | 10 | $512 |
| Xeris Pharmaceuticals, Inc. | 31 | $413 |
| Bayer | 16 | $371 |
| Boehringer Ingelheim | 23 | $353 |
| Dexcom, Inc. | 6 | $267 |
| Sanofi-aventis U.S. LLC | 12 | $212 |
| Amgen(2 entities) | 20 | $201 |
| AbbVie | 11 | $157 |
| Abbott | 8 | $155 |
| Corcept Therapeutics | 6 | $131 |
| Amneal Pharmaceuticals LLC | 8 | $125 |
| AstraZeneca | 2 | $115 |
| Lifescan, Inc. | 4 | $108 |
| Amarin Pharma, Inc. | 5 | $99 |
| Pfizer | 4 | $88 |
| Merck | 5 | $83 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Antares Pharma, Inc. | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Clarus Therapeutics Inc. | 2 | $29 |
| Intuity Medical Inc | 2 | $26 |
| BD | 1 | $23 |
| IBSA Pharma Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V-GO$4,600
- V-GO DISPOSABLE INSULIN DELIVERY$750
- TRULICITY$276
- DEXCOM G6 TRANSMITTER$209
- MINIMED 780G$172
- InPen$120
- Kerendia$120
- FARXIGA$102
- Omnipod$101
How this compares
$12,203 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 37 | $58,531 |
| OzempicSemaglutide | 20 | $30,973 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 36 | $22,866 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $16,795 |
| HumalogInsulin Lispro | 62 | $14,700 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 22 | $10,874 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $9,617 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 18 | $5,865 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $5,285 |
| NovologInsulin Aspart | 16 | $4,984 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,242 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $3,914 |
| Novolog FlexpenInsulin Aspart | 11 | $3,497 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,783 |
| Glimepiride | 26 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Humalog | $1,366 | $73,23099 claims |
| Novo NordiskOzempic, Novolog | $590 | $35,95736 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $125 | $12513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Lindsay OneilOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.